Reference - Foquest

References

^CFOQUEST^® Product Monograph, Elvium Life Sciences, April 23, 2024.
CADDRA - Canadian ADHD Resource Alliance: Canadian ADHD Practice Guidelines, 4.1 Edition, Toronto ON; CADDRA, 2020.
Weiss MD, et al. Efﬁcacy and safety of a long-acting multilayer-release methylphenidate formulation (PRC-063) in the treatment of adolescent Attention-Deﬁcit/Hyperactivity Disorder: a randomized, double-blind clinical trial with a 6-Month open-label extension. J Child Adolesc Psychopharmacol 2021;31(9):610-622.
Weiss MD, et al. Efficacy and safety of PRC-063, extended-release multilayer methylphenidate in adults with ADHD including 6-month open-label extension. J Attent Disor 2021;25(10):1417-1428.
^CBiphentin^® Product Monograph, Elvium Life Sciences, April 15, 2024.
^CConcerta^® Product Monograph, Janssen Inc., August 25, 2023.
CADDRA. Public Formulary Overview - Correctional Services Canada. April 2023. Available at: https://www.caddra.ca/provincial-and-federal-public-formulary-overview Accessed January 12, 2024.
Data on File, Elvium Life Sciences
Updates to the Alberta Drug Benefit List. November 1, 2023. Available at: https://idbl.ab.bluecross.ca/idbl/DBL/nov_dblupdate.pdf Accessed January 12, 2024.
Express Scripts^® Drug Benefit List. Available at: https://nihb.express-scripts.ca/NIHBProvider/benefits/pharmacy?page=drugbenefit-grid&benefit=pharmacy. Accessed January 12, 2024.
Saskatchewan Formulary Bulletin. Bulletin #211. March 1, 2022. Available at: https://formulary.drugplan.ehealthsask.ca/Bulletins/Bulletin-0211-Mar-2022.pdf. Accessed January 12, 2024.
Manitoba Drug Benefits and Manitoba Drug Interchangeability Formulary Amendment. Bulletin #114. Available at: https://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin114.pdf. Accessed January 12, 2024.
Ontario Drug Benefit Formulary:Edition 43. Available at: https://www.formulary.health.gov.on.ca/formulary. Accessed January 12, 2024.
RAMQ List of Medications. Available at: https://www.ramq.gouv.qc.ca/sites/default/files/documents/non_indexes/liste-med-2023-04-13-en.pdf. Accessed January 12, 2024.
New Brunswick Drug Plans Formulary. Available at: https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf. Accessed Accessed March 8, 2024.
Prince Edward Island Formulary. Available at: https://www.princeedwardisland.ca/sites/default/files/publications/pei_pharmacare_formulary.pdf. Accessed January 12, 2024.
Nova Scotia Formulary. Available at: https://novascotia.ca/dhw/pharmacare/documents/formulary.pdf. Accessed January 12, 2024.
Newfoundland and Labrador Prescription Drug Program. Available at: https://nlpdp.bell.ca. Accessed January 12, 2024.
Wigal SB, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34(1):47-53.
Reiz JL, et al. Comparative bioavailability of single-dose methylphenidate
from a multilayer-release bead formulation and an osmotic system
A two-way crossover study in healthy young adults. Clin Ther 2008;30(1):59-69.